webinar
Live Imaging of the Extracellular Matrix With a Glycan-Binding Fluorophore
June 9th, 2026 10:00 AM EDT
Register
Shopping Cart 0
Tel:
Email:
  1. Home
  2. Products
  3. Drug Discovery
  4. Inhibitor
  5. Cardiovascular and blood system
  6. 5-HT Receptor
  7. Bromperidol
Bromperidol
Bromperidol Chemical Structure

Bromperidol

Catalog NO.: 10457-90-6 CAS NO.: 10457-90-6 Brand: BOC Sciences

Category
Inhibitor
Tag/Targets
5-HT Receptor Dopamine Receptor
Molecular Formula
C21H23BrFNO2
Molecular Weight
420.32

Price Inquiry

WARNING: Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

cGMP Capacity

  • kg to MT scale
  • GMP batches production
  • Over 20 years of experience
  • HPAPI production with OEL < 1 μg/m³
  • Cleanroom Class 100 to Class 100,000
  • Special type of reactions in cGMP workshop
  • Cleaning level: Class A B C
  • cGMP synthesis workshop
Read More

Product Description

Bromperidol, a derivative of butyrophenone, is an antipsychotic commonly used in the treatment of schizophrenia as it could bind to the D2 dopamine and 5-HT2A serotonin receptor.

Quantity
Grams-Kilos
Melting Point
156-158°C
Density
1.366 g/cm3
InChI Key
RKLNONIVDFXQRX-UHFFFAOYSA-N
InChI
InChI=1S/C21H23BrFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2
SMILES
C1CN(CCC1(C2=CC=C(C=C2)Br)O)CCCC(=O)C3=CC=C(C=C3)F
NCT NumberTitleCondition Or DiseasePhaseStart DateSponsorStatus
NCT02307396Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic PatientsSchizophreniaPhase 4November 2014Technische Universität MünchenUnknown status
NCT02374567Pharmacovigilance in Gerontopsychiatric PatientsDementiaPhase 3January 2015Hannover Medical SchoolTerminated
Write a review Ask a question

Good afternoon, do you know something about Bromperidol? thank you.

It is primarily used in the treatment of schizophrenia and operates by targeting and inhibiting the D2 dopamine and 5-HT2A serotonin receptors, which are crucial in managing psychotic symptoms. Bromperidol has been involved in various studies to explore its efficacy and application in treating other conditions such as dementia, depression, anxiety disorders, and psychosomatic disorders.

5/5/2017

1.Bromperidol decanoate (depot) for schizophrenia.
Purgato M1, Adams CE. Cochrane Database Syst Rev. 2012 Nov 14;11:CD001719. doi: 10.1002/14651858.CD001719.pub4.
BACKGROUND: Antipsychotic drugs are the mainstay treatment for schizophrenia. Long-acting depot injections of drugs such as bromperidol decanoate are extensively used as a means of long-term maintenance treatment.
2.The pharmacokinetics of long-acting antipsychotic medications.
Spanarello S, La Ferla T1. Curr Clin Pharmacol. 2014;9(3):310-7.
The depot antipsychotics are synthesized by esterification of the active drug to a long chain fatty acid and the resultant compound is then dissolved in a vegetable oil, with the exception of some molecules of new generation characterized by microcrystalline technologies. The absorption rate constant is slower than the elimination rate constant and therefore, the depot antipsychotics exhibit 'flip-flop' kinetics where the time to steady-state is a function of the absorption rate, and the concentration at steady-state is a function of the elimination rate. The pharmacokinetics of depot antipsychotic medications are such that an intramuscular injection given at intervals from 1 to 4 weeks will produce adequate plasma concentrations that are sufficient to prevent relapse over the dosage interval. Such medication is useful in patients who do not reliably take their oral medication. The pharmacokinetics and clinical actions of various depot formulations of antipsychotic drugs have been extensively studied.
3.The use of dried blood spots for quantification of 15 antipsychotics and 7 metabolites with ultra-high performance liquid chromatography - tandem mass spectrometry.
Patteet L1,2, Maudens KE1, Stove CP3, Lambert WE3, Morrens M4, Sabbe B4, Neels H1,2. Drug Test Anal. 2015 Jun;7(6):502-11. doi: 10.1002/dta.1698. Epub 2014 Jul 31.
Therapeutic drug monitoring of antipsychotics is important in optimizing individual therapy. In psychiatric populations, classical venous blood sampling is experienced as frightening. Interest in alternative techniques, like dried blood spots (DBS), has consequently increased. A fast and easy to perform DBS method for quantification of 16 antipsychotics (amisulpride, aripiprazole, asenapine, bromperidol, clozapine, haloperidol, iloperidone, levosulpiride, lurasidone, olanzapine, paliperidone, pipamperone, quetiapine, risperidone, sertindole and zuclopenthixol) and 8 metabolites was developed. DBS were prepared using 25 μL of whole blood and extraction of complete spots was performed using methanol: methyl-t-butyl-ether (4:1). After evaporation, the extract was reconstituted in the mobile phase and 10 μL were injected on an ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS). Separation using a C18 column and gradient elution with a flow rate of 0.
4.Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia.
Declercq T1, Petrovic M, Azermai M, Vander Stichele R, De Sutter AI, van Driel ML, Christiaens T. Cochrane Database Syst Rev. 2013 Mar 28;3:CD007726. doi: 10.1002/14651858.CD007726.pub2.
BACKGROUND: Antipsychotic agents are often used to treat neuropsychiatric symptoms (NPS) in dementia, although the literature is sceptical about their long-term use for this indication. Their effectiveness is limited and there is concern about adverse effects, including higher mortality with long-term use. When behavioural strategies have failed and drug therapy is instituted, regular attempts to withdraw these drugs are recommended. Physicians, nurses and families of older people with dementia are often reluctant to try to stop antipsychotics, fearing deterioration of NPS. Strategies to reduce antipsychotic use have been proposed, but a systematic review of interventions aimed at withdrawal of antipsychotic agents in older people with dementia has not yet been performed.
Preparing Stock Solutions
ConcentrationVolumeMass1 mg5 mg10 mg
1 mM2.3791 mL11.8957 mL23.7914 mL
5 mM0.4758 mL2.3791 mL4.7583 mL
10 mM0.2379 mL1.1896 mL2.3791 mL
About Us

BOC Sciences is a trusted global supplier of research chemicals, biochemicals, and pharmaceutical ingredients, serving the life sciences, biotech, and pharmaceutical industries. Headquartered in New York, we offer a comprehensive product portfolio that includes inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP products, impurities and metabolites, APIs, natural compounds, ADC-related chemicals, and stem cell molecules.

We specialize in the synthesis, biosynthesis, purification, and characterization of small molecules. With years of industry experience, our scientific and technical teams support projects ranging from early discovery to process development and regulatory submission.

BOC Sciences operates GMP-compliant and ISO-certified production facilities, ensuring consistent quality and regulatory alignment. Our products and services are trusted by clients in over 60+ countries, including top pharmaceutical companies, academic institutions, and research organizations.

We are committed to providing high-quality chemicals, responsive technical support, and flexible custom solutions to accelerate innovation in drug discovery and development.

Our Clients

Online Inquiry

Basic Information
How did you hear about BOC Sciences?
Verification code